Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET
Company Participants
Andrew Guggenhime – President and CFO
Grant Pickering – CEO
Jim Wassil – EVP and COO
Conference Call Participants
Roger Song – Jefferies
Salim Syed – Mizuho
Umer Raffat – Evercore
Seamus Fernandez – Guggenheim
Tom Shrader – BTIG
Joseph Stringer – Needham & Company
Operator
Good afternoon, my name is Jess, and I will be your conference operator today. At this time, I would like to welcome everyone to the Vaxcyte Fourth Quarter and Full Year 2024 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer period. [Operator Instructions] Today’s call is being recorded. I would now like to turn the call over to Andrew Guggenhime, President and Chief Financial Officer of Vaxcyte. Please go ahead, sir.
Andrew Guggenhime
Thank you, operator, and good afternoon, everyone. I’d like to welcome you to Vaxcyte’s earnings conference call to discuss our 2024 results and to provide a business update. I am joined today by our Chief Executive Officer, Grant Pickering; and our Executive Vice President and Chief Operating Officer, Jim Wassil. Earlier this afternoon, we issued a news release announcing our results. Copies of this and our other news releases, latest corporate presentation and SEC filings can be found in the Investors & Media section of our website.
Before we begin, I’d like to remind you that during this call, we’ll be making certain forward-looking statements about Vaxcyte, which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in any forward-looking statements. For a discussion of the risks and uncertainties associated with these statements, please see our press release issued today as well
Read the full article here
